3-methyl-1,2,3,4-tetrahydroquinazolin-2-one

CAS No. 24365-65-9

3-methyl-1,2,3,4-tetrahydroquinazolin-2-one( —— )

Catalog No. M28377 CAS No. 24365-65-9

3-methyl-1,2,3,4-tetrahydroquinazolin-2-one is a inhibitor of BRD4 .

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 51 In Stock
2MG 31 In Stock
5MG 48 In Stock
10MG 71 In Stock
25MG 122 In Stock
50MG 179 In Stock
100MG 267 In Stock
200MG Get Quote In Stock
500MG 663 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    3-methyl-1,2,3,4-tetrahydroquinazolin-2-one
  • Note
    Research use only, not for human use.
  • Brief Description
    3-methyl-1,2,3,4-tetrahydroquinazolin-2-one is a inhibitor of BRD4 .
  • Description
    3-methyl-1,2,3,4-tetrahydroquinazolin-2-one is a inhibitor of BRD4 .
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Chromatin/Epigenetic
  • Target
    Epigenetic Reader Domain
  • Recptor
    Platelet aggregation
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    24365-65-9
  • Formula Weight
    162.192
  • Molecular Formula
    C9H10N2O
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    CN1Cc2ccccc2NC1=O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Jian Tang, et al. Antitumor and antiplatelet activity of alkaloids from veratrum dahuricum. Phytother Res. 2010 Jun;24(6):821-6.
molnova catalog
related products
  • PBRM1-BD2-IN-5

    PBRM1-BD2-IN-5 is a potent inhibitor of the PBRM1 Bromodomain, with dissociation constant (Kd) values of 1.5 μM and 3.9 μM for PBRM1-BD2 and PBRM1-BD5 respectively, and an inhibitory concentration 50 (IC50) value of 0.26 μM for PBRM1-BD2.

  • ZEN-3694

    ZEN-3694 (ZEN 3694) is a bromo-structural domain extra-terminal inhibitor (BETi) with activity in androgen signaling inhibitor (ASI) resistance models and can be used in combination with enzalutamide to study metastatic desmoplasia-resistant prostate cancer.

  • OXF BD 02

    OXF BD 02 is a potent and selective BRD4(1) inhibitor (IC50: 382 nM) with anticancer and anti-inflammatory activity.